Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
REYATAZ | Bristol Myers Squibb | N-021567 RX | 2003-06-20 | 2 products, RLD |
REYATAZ | Bristol Myers Squibb | N-206352 RX | 2014-06-02 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EVOTAZ | Bristol Myers Squibb | N-206353 RX | 2015-01-29 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
atazanavir | ANDA | 2025-03-17 |
atazanavir sulfate | ANDA | 2025-01-24 |
evotaz | New Drug Application | 2023-05-12 |
reyataz | New Drug Application | 2023-11-07 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
hiv infections | EFO_0000764 | D015658 | B20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
Drug common name | Atazanavir |
INN | atazanavir |
Description | Atazanavir is a heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV). It has a role as an antiviral drug and a HIV protease inhibitor. |
Classification | Small molecule |
Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C |
PDB | — |
CAS-ID | 198904-31-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1163 |
ChEBI ID | 37924 |
PubChem CID | 148192 |
DrugBank | DB01072 |
UNII ID | QZU4H47A3S (ChemIDplus, GSRS) |